NYS Medicaid Pharmacy Programs
Clinical Drug Review Program (CDRP)
The Clinical Drug Review Program (CDRP) is aimed at ensuring specific drugs are utilized in a medically appropriate manner. Under the CDRP, certain drugs require prior authorization because there may be specific safety issues, public health concerns, the potential for fraud and abuse or the potential for significant overuse and misuse.
Prior authorization for some drugs subject to the CDRP must be obtained through a representative at the clinical call center. Prior authorization is required for original prescriptions, not refills. For some drugs subject to the CDRP, only prescribers, not their authorized agents, can initiate the prior authorization process. An authorized agent is an employee of the prescribing practitioner and has access to the patient's medical records (i.e. nurse, medical assistant).
Each CDRP drug has specific clinical information that must be provided to the clinical call center before prior authorization will be issued. Prescribers may be asked to fax that information. CDRP prior authorization worksheets are available online.
The following drugs are subject to the Clinical Drug Review Program:
- becaplermin gel (Regranex®)
- emtricitabine/tenofovir disoproxil fumarate (Truvada®)
- fentanyl mucosal agents
- lidocaine patch (Lidoderm®, ZTLido™)
- oxazolidinone antibiotics (Sivextro®, Zyvox®)
- palivizumab (Synagis®)
- sodium oxybate (Xyrem®)
- somatropin (Serostim®)
The following Preferred Drug Program Classes are subject to the Clinical Drug Review Program prior authorization requirements:
- Anabolic Steroids
- CNS Stimulants
- Growth Hormones
- Phosphodiesterase type-5 (PDE-5) Inhibitors for PAH
- Topical Immunomodulators
For questions and comments: